Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LBL-015 in Advanced Malignancies (Phase 1/2)
CTR20212249Phase 2Completed
- Sponsor
- Leads Biolabs
- Start
- Sep 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of LBL-015 in Nonhematologic neoplasms, lymphoma, cancer, sponsored by Leads Biolabs. Started Sep 2021; status: completed.
02
Drugs
LBL-015
03
Conditions
Nonhematologic neoplasmslymphomacancer
Beyond the preview
Go deeper on CTR20212249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212249.